Skip to content
Peptigraph home

Kisspeptin-10 vs PT-141: What the Research Shows

Kisspeptin-10 and PT-141 side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GnRH stimulatorNot FDA approved · research chemicalKisspeptin-10GnRH-stimulating peptide, not FDA-approved; in healthy men, subcutaneous kisspeptin-10 infusions dose-dependently raised LH, FSH and testosterone versus vehicle.[6]Sexual & hormonal health+371% searchesMelanocortin agonistFDA approved for HSDD (Vyleesi)PT-141Melanocortin agonist FDA-approved as Vyleesi for premenopausal women with low sexual desire; the integrated trials showed a statistically significant desire increase of 0.35.[10]Sexual & hormonal health+123% searches
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider Kisspeptin-10 if…

  • you want human hormone data (infusion in men; a hormone-level outcome): At 4 ug/kg/h for 22.5 h, LH rose from 5.4 to 20.8 IU/liter and testosterone from 16.6 to 24.0 nmol/liter.[13]
  • you want to see the dosing limitation in women: responses fell with repeated dosing: LH and FSH responses fell sharply by day 14 of twice-daily injections (LH +2.5 IU/liter, FSH +0.5 IU/liter).[14]

Consider PT-141 if…

  • you want a product with an FDA label: Vyleesi (bremelanotide) is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder[8]
  • you want randomized phase 3 data (bremelanotide in premenopausal women with low desire): Desire domain score rose more than placebo: 0.30 (study 301), 0.42 (study 302), 0.35 integrated, all P<.001.[10]
  • you are tested in sport and want to avoid a WADA-prohibited substance: Kisspeptin is prohibited by WADA at all times (check PT-141's own status separately)[2]
Kisspeptin-10 is prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 11 of 14 fields where the two differ. Category, PCAC vote, Jul 2026, Evidence strength are the same or both unknown.

FieldKisspeptin-10PT-141
ClassGnRH stimulatorMelanocortin agonist
Also calledkissVyleesi, PT141
FDA statusNot FDA approved · research chemicalFDA approved for HSDD (Vyleesi)
WADAProhibited by WADA (S2.2.1)Kisspeptin and its agonist analogues are named in S2.2.1 (testosterone-stimulating peptides in males).Not on the WADA Prohibited ListPT-141 (bremelanotide) is not named on the list and is FDA-approved (Vyleesi), so S0 does not apply. It does not fit the named S2 subclasses.
Anti-doping detection
  • Kisspeptin-10 is cleared very fast (30 minutes in rats), so labs target metabolites.PMID 38978171
  • A 2026 method detects kisspeptins in serum and urine; samples from people who actually took them were not yet tested.PMID 42057309
None reportedanti-doping literature, as of 2 Oct 2026
Half-lifemean elimination half-life 1.3-2.2 hourssubcutaneous (analog MVT-602) · Fertility and sterility 2024, PMID 37925096approximately 2.7 hours (range 1.9-4.0 h)subcutaneous · FDA label (Vyleesi)
Human studies we summarised13 human (10 randomized or controlled) of 16 summarised12 human (12 randomized or controlled) of 12 summarised
Typical study doses
Vial sizes sold5 mg, 10 mg10 mg
US searches per month22,200 · +371% searches67,600 · +123% searches
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026)

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Taken together?

Kisspeptin-10 and PT-141 together

People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 0 results, 2 Oct 2026).

Open the stack page
StackKisspeptin-10 + PT-141, taken as separate injectionsStack page

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3[Not Available].Biomedical chromatography : BMC · 2024PMID 38978171Accessed 2 Oct 2026
  4. 4Analysis and Characterization of Kisspeptin and Its Analogues in Serum and Urine Samples by Liquid Chromatography-High-Resolution Mass Spectrometry for Doping Control Purposes.Drug testing and analysis · 2026PMID 42057309Accessed 2 Oct 2026
  5. 5Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals.Fertility and sterility · 2024PMID 37925096Accessed 2 Oct 2026
  6. 6Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men.European journal of endocrinology · 2026PMID 42549827Accessed 2 Oct 2026
  7. 7Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial.JAMA network open · 2022PMID 36287566Accessed 2 Oct 2026
  8. 8These highlights do not include all the information needed to use VYLEESI ® safely and effectively. See full prescribing information for VYLEESI VYLEESI (bremelanotide injection), for subcutaneous use Initial U.S. Approval: 2019FDA label (Vyleesi), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  9. 9Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.Journal of women's health (2002) · 2022PMID 35230162Accessed 2 Oct 2026
  10. 10Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.Obstetrics and gynecology · 2019PMID 31599840Accessed 2 Oct 2026
  11. 11Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.The journal of sexual medicine · 2019PMID 31277966Accessed 2 Oct 2026
  12. 12PubMed search: ("kisspeptin-10"[tiab] OR "kisspeptin 10"[tiab]) AND (bremelanotide[tiab] OR "PT-141"[tiab] OR PT141[tiab] OR Vyleesi[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.The Journal of clinical endocrinology and metabolism · 2011PMID 21632807Accessed 2 Oct 2026
  14. 14Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis.The Journal of clinical endocrinology and metabolism · 2009PMID 19820030Accessed 2 Oct 2026

Found an error? Report a correction.